Vij 2003.

Methods	Biologically randomised study (recruitment period not reported). Single centre. Country: USA
Participants	Inclusion criteria: people receiving an allogeneic peripheral blood stem cell transplant Exclusion criteria: infection criteria for excluding people from the study not reported Total allocated: N = 225 Total analysed: N = 225 Arm 1 (Granulocyte transfusions): allocated and analysed = 83, Acute leukaemia = 36, Non Hodgkins lymphoma = 17, Chronic myeloid leukaemia = 17, other = 13 Arm 2 (Control): allocated and analysed = 142, , Acute leukaemia = 61, Non Hodgkins lymphoma = 37, Chronic myeloid leukaemia = 18, other = 26
Interventions	Comparison between standard treatment and prophylactic granulocyte transfusions Granulocyte dose: participants received two granulocyte transfusions. The mean dose and range were not reported Granulocyte method of collection: continuous flow apheresis Donor premedication: G‐CSF Initiation of granulocyte transfusions: Day plus 3 or 5 (depending on protocol) Frequency of granulocyte transfusions: Twice during neutropenic interval Termination of granulocyte transfusions: Day plus 6 or 7 (depending on protocol)
Outcomes	Primary Outcome: Not reported Other Outcomes: Incidence of CMV viraemia; median time to detection of CMV viraemia
Definition of infection	Febrile day ‐ Not reported Febrile episode ‐ Not reported Proven infection: Not reported
Definition of neutropenia	Not reported
Co‐interventions	Prophylactic antibiotics: not reported Therapeutic antibiotics: not reported Therapeutic granulocyte transfusions: not reported
Notes	Funding Sources: the publication costs of the article were defrayed in part by part charge payment. Therefore and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. Conflict of Interests: Not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Randomisation was biological, determined by the availability of an ABO‐compatible allogeneic peripheral blood stem cell donor. The same donor served as both the stem cell and granulocyte donor
Allocation concealment (selection bias)	High risk	Treatment allocation was dependent on availability of an appropriate granulocyte donor
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	It was not reported whether participants were blinded to the intervention. It was not reported whether clinicians or investigators were blinded to the intervention.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	It was not reported whether outcome assessors were blinded to the intervention
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Loss to follow‐up was not reported
Selective reporting (reporting bias)	Unclear risk	The protocol was not available to assess whether any pre‐specified outcomes were not reported or outcomes were reported that were not pre‐specified
Other bias	High risk	The publication costs of the article were defrayed in part by part charge payment, this article was marked as an "advertisement" in accordance with 18 USC section 1734.